Bronwen E Shaw, MD, PhD

Professor; Scientific Director CIBMTR

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MD - Doctor of Medicine
PhD

Biography

Dr. Shaw received her MD (MBChB) from the University of Cape Town, South Africa in 1993. All of her subsequent postgraduate haematology specialist training was completed in London, UK where she also received her PhD in Clinical Sciences and Immunology from University College London in 2004. Her PhD was entitled Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors.

Research Interests

Prior to taking up her position at the CIBMTR and MCW, Dr. Shaw was a Consultant Haematologist specializing in Stem Cell Transplantation and Survivorship issues at the Royal Marsden Hospital in Sutton, UK. She simultaneously held the position of Chief Medical Officer at Anthony Nolan, the UK’s national unrelated donor registry. In this position she had oversight of the donor research activities and the medical operations of the organization. She also held a senior scientific role, with direct supervision of several PhD and MD students working in the area of immunogenetics, donor selection, and the donor experience.

The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.

(Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski H, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy H, Preussler JM, Schears RM, Sharma A, van der Poel M, Bruce JG, Pulsipher MA, Shaw BE, Wingard JR, Switzer GE.) Transplant Cell Ther. 2022 Jun 07 PMID: 35688325 06/11/2022
Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association.

(Jöris MM, Schmidt AH, Bernas SN, Feinberg J, Sacchi N, Elmoazzen H, Fournier D, Oguz F, Oliveira D, Yang KL, Mousavi SA, Moomivand S, Abecasis M, Villa J, Fechter MM, Seval GC, Jeyarajah T, Devine SM, Shaw BE, Galarza P, Malan R, Harvey C, Forman SJ, Foeken L.) Bone Marrow Transplant. 2022 Jun;57(6):1021-1024 PMID: 35397653 PMCID: PMC8994088 SCOPUS ID: 2-s2.0-85127635726 04/11/2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.

(Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M.) Transplant Cell Ther. 2022 Apr 18 PMID: 35447374 SCOPUS ID: 2-s2.0-85130441260 04/22/2022
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.

(Hough R, Lopes A, Patrick P, Russell N, Raj K, Tholouli E, A Snowden J, Collin M, El-Mehidi N, Lawrie A, Clifton-Hadley L, Veys P, Craddock C, Mackinnon S, Cook G, Shaw B, Marks D.) Blood Adv. 2022 04 12;6(7):2414-2426 PMID: 34700343 PMCID: PMC9006284 SCOPUS ID: 2-s2.0-85129231043 10/27/2021
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.

(Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW.) Blood. 2022 03 10;139(10):1452-1468 PMID: 34724567 PMCID: PMC8914182 SCOPUS ID: 2-s2.0-85124046605 11/02/2021
Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry.

(Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, Shaw B.) Transplant Cell Ther. 2022 02;28(2):112.e1-112.e9 PMID: 34757219 PMCID: PMC8915447 SCOPUS ID: 2-s2.0-85121127060 11/11/2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

(Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM.) Transplant Cell Ther. 2021 11;27(11):885-907 PMID: 34461278 PMCID: PMC8556300 SCOPUS ID: 2-s2.0-85116810681 08/31/2021
Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy.

(Kelly DL, Syrjala K, Taylor M, Rentscher KE, Hashmi S, Wood WA, Jim H, Barata A, Flynn KE, Burns LJ, Shaw BE, Petersdorf E, Yero AC, Emmrich AD, Morris KE, Costanzo ES, Knight JM.) Transplant Cell Ther. 2021 09;27(9):747-757 PMID: 34139388 PMCID: PMC8428782 SCOPUS ID: 2-s2.0-85110419978 06/18/2021
Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

(Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B.) Transplant Cell Ther. 2021 08;27(8):679.e1-679.e8 PMID: 33895402 PMCID: PMC8425287 SCOPUS ID: 2-s2.0-85107434203 04/26/2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.

(Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J.) J Clin Oncol. 2021 06 20;39(18):1971-1982 PMID: 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 04/28/2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.

(Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, Wingard JR.) Transplant Cell Ther. 2021 06;27(6):507-516 PMID: 33865804 PMCID: PMC8217124 SCOPUS ID: 2-s2.0-85108052714 04/19/2021
Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.

(Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, Shaw BE.) JCO Clin Cancer Inform. 2021 05;5:494-507 PMID: 33950708 PMCID: PMC8443829 SCOPUS ID: 2-s2.0-85105478562 05/06/2021